Safety and Tolerance of Indinavir Plus Ritonavir in HIV-Positive Patients Failing Therapy With Amprenavir, Nelfinavir, or Saquinavir
This study has been completed.
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
First received: January 17, 2000
Last updated: May 21, 2012
Last verified: May 2012
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||August 2006|
|Estimated Primary Completion Date:||No date given|
Acosta EP, Wu H, Hammer SM, Yu S, Kuritzkes DR, Walawander A, Eron JJ, Fichtenbaum CJ, Pettinelli C, Neath D, Ferguson E, Saah AJ, Gerber JG; for the Adult AIDS Clinical Trials Group 5055 Protocol Team. Comparison of Two Indinavir/Ritonavir Regimens in the Treatment of HIV-Infected Individuals. J Acquir Immune Defic Syndr. 2004 Nov 1;37(3):1358-1366.
King JR, Gerber JG, Fletcher CV, Bushman L, Acosta EP. Indinavir protein-free concentrations when used in indinavir/ritonavir combination therapy. AIDS. 2005 Jul 1;19(10):1059-1063.
Wu H, Huang Y, Acosta EP, Park JG, Yu S, Rosenkranz SL, Kuritzkes DR, Eron JJ, Perelson AS, Gerber JG. Pharmacodynamics of Antiretroviral Agents in HIV-1 Infected Patients: Using Viral Dynamic Models that Incorporate Drug Susceptibility and Adherence. J Pharmacokinet Pharmacodyn. 2006 Apr 1; [Epub ahead of print]